Skip to main content
Equibles
VNDA logo

VNDA · Vanda Pharmaceuticals Inc. · Metrics

Track VNDA — free

Use VNDA with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research VNDA.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$3.89 +0.07 (+1.83%) Play latest call Q3 2026 earnings call transcript
Russell 2000 member Rebalance outlook locked
Market Cap
$230.99M
Shares
60.47M
Volume · Nov 9 152K Avg daily vol (3M) 1.06M

VNDA metrics

89 of 125 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$3.82
Market cap
$230.99M

Price action

23 metrics
Price change (1W)
+0.8%
Price change (30D)
-16.4%
Price change (3M)
-23.6%
Price change (6M)
-39.2%
Price change (YTD)
-56.7%
Price change (1Y)
-13.4%
Trailing year
Price change (5Y)
-78.7%
52-week high
$9.56
52-week low
$3.59
Change from 52-week high
-60.0%
Change from 52-week low
+6.4%
Annualized volatility
80.1%
Annualized volatility (3M)
43.1%
Implied volatility (30D)
124.8%
IV rank (1Y)
77.5
IV percentile (1Y)
95.4
Beta
0.8
RSI (14D)
38.7
Price vs SMA 50
-17.5%
Price vs SMA 200
-37.5%
Avg volume (3M)
1.06M
Relative volume
0.9
Average dollar volume
$4.96M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
60.47M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
1.0×
reciprocal yield 99.3%
P / book
1.2
reciprocal yield 86.5%
FCF yield
-60.6%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-119.0%

Historical valuation

8 metrics
P / E historical average (3Y)
42.5×
reciprocal yield 2.4%
P / E historical average (5Y)
35.2×
reciprocal yield 2.8%
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-10-28

Profitability

9 metrics
Gross margin
—
Operating margin
-77.6%
Trailing 12 months
Net margin
-119.9%
Gross profit (TTM)
$223.33M
Operating profit (TTM)
−$177.91M
Net income (TTM)
−$274.83M
Trailing 12 months
Diluted EPS (TTM)
$-4.63
FCF margin
-61.0%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$3.83
Gross profit per diluted share (TTM)
$4.05
Operating profit per diluted share (TTM)
$-2.98
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
$-4.62
Operating cash flow per diluted share (TTM)
$-2.33
Free cash flow per diluted share (TTM)
$-2.34
Capital expenditures per diluted share (TTM)
$0.01
R&D per diluted share (TTM)
$2.04
Stock compensation per diluted share (TTM)
$0.16
Book value per share
$5.54

Growth

11 metrics
Revenue growth YoY
+24.1%
Year over year
Net income growth YoY
—
Revenue (TTM)
$229.28M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+2.3%
Year over year · more shares
Revenue CAGR (3Y)
-5.3%
Revenue CAGR (5Y)
-2.7%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-137.5%
Return on assets
-71.9%
Debt / equity
—
Current ratio
1.5
EBITDA (TTM)
$44.95M
Free cash flow (TTM)
−$139.96M
Quick ratio
1.5
Interest coverage
—
Net debt / EBITDA
-1.0
Return on invested capital
—
Trailing 12 months
Net cash
$61.93M
Latest balance sheet
Cash & equivalents
$61.93M
Total assets
$382.33M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$139.14M
Capital expenditures (TTM)
$824,000
R&D (TTM)
$122.02M
SG&A (TTM)
$262.75M
Stock compensation (TTM)
$9.29M
R&D / revenue
53.2%
Stock compensation / revenue
4.1%

Ownership (13F)

9 metrics
13F filers
172
13F filer change QoQ
-1
Institutional ownership
82.5%
Conviction holders (share of 13F filers)
0.6%
Crowding (high-turnover and private-fund holders)
37.8%
Private-fund adviser ownership
32.9%
Active holders' share change QoQ
+6.1%
Holder tenure
14.4
Price vs estimated holder cost
-1.7%

Ownership (registered funds)

1 metrics
Index-fund ownership
17.8%

Short interest

3 metrics
Short interest
13.7%
Latest settlement · 8.3 days to cover
Days to cover
8.3d
Short-squeeze score
74 / 100

Insider activity

2 metrics
Net insider buying (90D)
$38,094
Insider-sentiment score
77 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 1347178 CUSIP 921659108 13F (30d) 68 filings 52 filers Visit website Investor relations